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months of AICC infused prophylaxis (PX) with 6 months of on-demand (OD) ther-
apy, separated by a 3-month washout period during which patients used on-de-
mand therapy. HRQoL was summarized in two continuous variables: Physical
Component Score (PCS-36) and Mental Component Score (MCS-36). The difference
between two study periods for 6-month change from baseline in PCS-/MCS-36 are
compared using Wilcoxon signed-rank test to measure the difference between two
groups regardless of the sequence of medications. To investigate the effect of ran-
dom sequence in the change of HRQoL, the difference between two study periods
for 6-month change from baseline in PCS-/MCS-36 is compared by random se-
quence using Wilcoxon-Mann-Whitney U test with exact statement. RESULTS:
Twenty-six patients completed both study periods. 17 of them were 14 years old
and thus completed QoL questionnaires and are included in this analysis. The
difference between PX and OD in 6-month change from baseline was 2.83 for
PCS-36 (p0.378) and 1.29 for MCS-36 (p0.890), favored PX on both measures.
Regardless of random sequence of medication, HRQoL showed a moderate im-
provement with PX. When comparing the difference of 6-month change by treat-
ment sequence, patients who initiated with PX then switched to OD had a greater
improvement compared to the opposite sequence (PX-OD: 6.59, OD-PX: 0.19 for
PCS-36 (p0.475); PX¡OD: 2.66, OD¡PX: 0.33 for MCS-36 (p0.601)).
CONCLUSIONS: A cross-over effect, albeit statistically non-significant, was ob-
served when the difference of 6-month change was compared by treatment se-
quence. Patients who started with more favorable medication tended to show a
greater improvement, whereas patients in opposite sequence showed a slight im-
provement.
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OBJECTIVES: Russian Society of Pharmacoeconomics and Outcomes Research
jointly to Russian Hemophilia Society carried out postal and telephone health sur-
vey of all known Russian patients with hemophilia in the period 2009-2010. Aim of
the study was to assess health status, treatment patterns and quality of life in
patients with inhibitory form of hemophilia. METHODS: Postal and telephone
health survey. The questionnaire contained questions on clotting factor level and
presence of antibodies to it, names of used medications. Health-related quality of
life was assessed with self-administrated validated version of Russian version of
Euroqol-5D questionnaire, comprising a dimensions of health and visual-analog
scale. Statistical analysis of data was performed with 2 criteria. RESULTS: The
results of principal methods of treating inhibitory form of hemophilia in 60 patients
with haemophilia A were analysed. Health-related quality of life was assessed for
patients older than 11 years (n 56). More than half of patients reported problems
within each of EQ-5D dimensions of health. Thus 76.6% of patients reported of
problems with mobility; 48.4% of patients informed of difficulties with self-care;
75% of patients had difficulties with usual activity; 81.7% of patients reported of
presence of pain or discomfort; 50.1% of patients had an anxiety or depression. The
average value of quality of life evaluated with visual-analog scale (VAS) was 0.57
(SD 0.17), median – 0.52.CONCLUSIONS: The study of quality of life in patients with
hereditary coagulopathies was performed for the first time in Russian. Results of
the study shown high rate of pain/discomfort, of problems with movement, usual
activity and low rate of problem with self-care and anxiety/depression.
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OBJECTIVES: To assess the quality of life in patients suffering from intense pain
which has progressed since less than 7 days treated by a combination of paraceta-
mol and codeine. METHODS: A multi-centre longitudinal observational prospec-
tive study carried out in metropolitan France using data collected by general prac-
titioners who agreed to participate. RESULTS: A total of 804 patients treated by a
paracetamol-codeine combination (600mg/50mg and 400mg/20mg) were included;
at inclusion the quality of life assessed using SF-12 was affected as much in terms
of the mental component (41.4 11.6) as the physical component (35.4 8.04) – the
norm of the scores for each component is equal to 50 – on D7, the quality of life
assessed in a similar manner using SF-12 was 43.31  9.89 for the mental compo-
nent and 40.93  7.92 for the physical component. A statistically significant im-
provement was noted for each of the 2 mental (p0.001) and physical (p0.001)
components between the first day of treatment and the seventh day. On D7, 95.9%
declared treatment to be effective, 87.2% were satisfied with their treatment and
89.2% did not observe any side effects to the treatment. 9 out of 10 patients did not
complain about side effects related to the treatment.CONCLUSIONS:The improve-
ment in quality of life observed directly through SF-12 was also confirmed by pa-
tient satisfaction: from the first day, 61% of patients declared themselves to be
satisfied. On the 7th day of treatment, 87.10% were satisfied with their treatment.
2/3 patients declared the treatment to be effective from the 1st day, and 91% of
them declared this on the 3rd day: It shows the pertinence of the treatment.
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OBJECTIVES: A daily assessment of the speed of action and effectiveness of treat-
ment of a combination of paracetamol and codeine in patients suffering from
intense pain, which has progressed since less than 7 days. METHODS: A multi-
centre longitudinal observational prospective study carried out in metropolitan
France using data collected by general practitioners who agreed to participate.
RESULTS: A total of 804 patients treated by a paracetamol-codeine combination
(600mg/50mg and 400mg/20mg) were included. The severity of pain measured at
inclusion using a visual numeric scale was 7  1.3. The severity of pain measured
after half a day of treatment was 5.29 1.87 and 5.65 1.85 at the end of the first 24
hours of treatment. A significant improvement in pain was observed from the first
half-day (p0.001). The severity of pain on the 2nd, 4th and 7th evenings was
respectively 4.09 1.87; 2.74 1.8 and 1.78 1.7. On D1, 70.8% declared treatment
to be effective, 62.56% were satisfied with their treatment and 80.5% did not ob-
serve any side effects to the treatment. On D3, 91.5% declared treatment to be
effective, 82.4% were satisfied with their treatment and 83.12% did not observe any
side effects to the treatment. On D7, 95.9% declared treatment to be effective, 87.2%
were satisfied with their treatment and 89.2% did not observe any side effects to the
treatment. 9 out of 10 patients did not complain about side effects related to the
treatment.CONCLUSIONS:A reduction in pain within the first 12 hours showed the
pertinence of treatment using a paracetamol-codeine combination. This perti-
nence was confirmed by 2/3 patients who declared the treatment to be effective
from the 1st day, and 91% of them declared this on the 3rd day.
Systemic Disorders/Conditions – Health Care Use & Policy Studies
PSY51
EPIDEMIOLOGY AND TREATMENT PATTERNS OF INHIBITOR HEMOPHILIA IN
RUSSIA: PATIENT-REPORTED DATA
Vorobyev PA1, Krasnova L2, Borisenko O1, Zhulyov Y3, Bezmelnitsyna L1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Moscow
State Medical University named after I.M.Sechenov, Moscow, Russia, 3Russian Hemophilia
Society, Moscow, Russia
OBJECTIVES: Russian Society of Pharmacoeconomics and Outcomes Research
jointly to Russian Hemophilia Society carried out postal and telephone health sur-
vey of all known Russian patients with inhibitor hemophilia in the period 2009-
2010. Aim of the study was to assess health status, treatment patterns and quality
of life in patients with inhibitory form of hemophilia. METHODS: Postal and tele-
phone health survey. The questionnaire contained questions on clotting factor
level and presence of antibodies to it, number of bleeding in last month, number of
injections of clotting factors per month, names of used medications, ways of re-
ceiving medications, number of ambulance calls and hospitalizations, and the way
of administration of medicines. The patients’ education level and employment
data was collected. Analysis of experimental data was performed with such statis-
tical parameters as 2 and Student’s criteria. RESULTS: The presence of antibodies
was detected in 60 patients with haemophilia A (47 patients (78.3%) were adults, 4
(6.7%) – adolescents, 9 (15%) - children upward 11 years old). Mean age was 30 years.
90% of patients experienced bleeding in the last month (median – 3). 85% of patients
used clotting factor VIII in the last month (median – 12 times). 13.3% of patients
called for an ambulance in a last month and 21.7% of patients were hospitalized
during last month. 68.3% of patients perform the injections of clotting factor
themselves. CONCLUSIONS: The study revealed epidemiologic characteristics and
treatment patterns of inhibitor hemophilia in Russia.
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OBJECTIVES: Russian Society of Pharmacoeconomics and Outcomes Research
jointly to Russian Hemophilia Society carried out postal and telephone health sur-
vey of all known Russian patients with hemophilia in the period 2009-2010. Aim of
the study was to assess health status, treatment patterns and quality of life in
patients with inhibitory form of hemophilia. METHODS: Postal and telephone
health survey. The questionnaire contained questions on number of bleeding in
last month, number of injections of clotting factors per month, names of used
medications, number of ambulance calls and hospitalizations. The patients’ edu-
cation level and employment data was collected. Analysis of experimental data
was performed with such statistical parameters as 2 and Student’s criteria.
RESULTS: The presence of antibodies was detected in 60 patients with hemophilia
A (47 patients (78,3%) were adults, 4 (6,7%) – adolescents, 9 (15%) - children upward
11 years old). All patients were divided into 3 subgroups: 31.7% patients received
immunological tolerance (IIT), 31.7% - therapy with NovoSeven, 36.6% - mixed
therapy. During one month bleeding was indicated in 78.9%, 100%, 90.9% patients
in 3 subgroup respectively; clotting factor VIII was used in 100%, 73.7%, 95.4%
patients respectively; emergency calls were made by 10.5%, 5.3%, 22.7% patients;
26.3%, 31.6%, 13.6% patients were hospitalized; 63.2%, 68.4%, 72.7% patients made
injections of clotting factor themselves. CONCLUSIONS: The rate of ambulance
calls and hospitalizations was comparatively low. Most patients made injections of
clotting factor themselves.
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OBJECTIVES: Over two-thirds of the US population are overweight or obese. While
current pharmacotherapy options for weight loss are limited, new weight loss
products have not been approved partly over safety concerns, including some
linked to weight-related illnesses such as hypertension. However, very little is
known about the association of available weight-loss pharmacotherapy with
changes in drug therapy for weight-related illnesses. METHODS: A retrospective
cohort analysis of a deidentified pharmacy claims database evaluated adult pa-
tients initiating weight-loss pharmacotherapy (no weight-loss drug prescriptions 6
months prior) between November 1, 2007 – October 31, 2010. Patients with contin-
uous eligibility for 6 months pre- (baseline) and 6 months post- weight-loss drug
initiation were evaluated for changes in concomitant drug therapy associated with
weight-related illnesses (hypertension, dyslipidemia, type 2 diabetes, anxiety, gas-
trointestinal disorders, depression, and hypothyroidism). Six-month outcomes in-
cluded concomitant therapy incidence, and net change (% patients adding1 drug
minus % discontinuing 1 drug in each illness category) analyzed using t-test
(significance at p0.05). RESULTS: A total of 91,160 patients initiated weight-loss
pharmacotherapy: phentermine (N67,434), sibutramine (N13,438), orlistat
(N8,047), phendimetrazine (N4,631), and diethylpropion (N 4,350); meanSD
age 4412 years (96%, 18-64 y/o), 82% female. Patients received 1.50.8 concomi-
tant weight-related illness drugs at baseline for hypertension (21.6%) depression
(14.9%), dyslipidemia (11.5%), hypothyroidism (9.2%), gastrointestinal disorders
(9.6%), anxiety (6.7%), and diabetes (5.5%). Incident/net therapy change over 6
months for each illness category: hypertension (3.2%/-6.5%), depression (0/-16.0%),
dyslipidemia (1.1%/-12.2%), hypothyroidism (1.2%/0.7%), gastrointestinal disor-
ders (0.2%/-17.1%), anxiety (1.1%/-19.4%), and diabetes (0.6%/-8.9%). All net changes
from baseline are significant (p0.05), with the exception of hypothyroidism
therapy. CONCLUSIONS: Concomitant therapy for obesity-related illnesses gener-
ally has a low incidence and declines significantly over 6 months after initiating
weight-loss pharmacotherapy. Antihypertensive and hypothyroidism therapy ap-
pear to follow different patterns, and whether this reflects disease progression,
effect of weight-loss therapy, genetics, or other factors warrants further investiga-
tion.
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OBJECTIVES: Haemophilia is one of the rare diseases in Iran; the government le-
gally has to cover its costs completely. Total drug subsidies are 320 millions USD
and 30% of subsidies have been allocated for the blood coagulating factors. There
are 3900 and 1100 registered patients with haemophilia A and B respectively which
190 of them are haemophilia with inhibitors. 17% of total drug subsidies have been
allocated for two bypassing agents; recombinant Factor VIIa and activated pro-
thrombin complex concentrate. The ministry of health has proposed a new guide-
line for managing costs of haemophilia with inhibitors so this study tries to esti-
mate cost of bypassing agents in this protocol and compares it with the current
situation. METHODS: For estimating the costs of new protocol, the price of medi-
cines and the patients’ information and statistics were taken from the Ministry of
Health and National Haemophilia Foundation. Information about responding to
different treatments and effectiveness of these two medicines were extracted from
evidence based literatures and systematic reviews. RESULTS: Based on new proto-
col the average cost for each bleeding episode is 1960 USD; it means 9 million USD
for 190 patients annually. A sensitivity analysis shows it can vary from 4 to 14
million USD. The current expenditure for these two bypassing agent is more than
45 million USD annually.CONCLUSIONS: The study shows the cost of new protocol
for 190 patients with inhibitors is 9 million USD annually; it could be 14 million USD
in the worst situation. This is 25 percent of current cost that has been paid for these
two bypassing agents. This notable gap may occur because of some reasons such as
smuggling to neighbors, off label uses, irrational drug use, inefficient patient man-
agement and moral hazards. The absence of efficient guideline not only causes
wasting limited resources but also increases risky behaviors.
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OBJECTIVES: Peripheral blood stem cell transplantations (PBSCT) are very expen-
sive life-saving medical procedures carried out in patients with haematological
disease. The current tariffs are expected to be too low due to developments in
treatment protocols. A revision of the tariffs is urgently necessary. We calculated
the cost of PBSCT for treating haematological diseases in Dutch daily practice, to
provide a proper basis for revising hospital budgets. METHODS: From three Dutch
university hospitals, we randomly selected 191 patients who underwent an autol-
ogous (auto) or allogeneic (allo) PBSCT in 2008 or 2009. The alloPBSCT were subcat-
egorised into sibling, matched unrelated donor (MUD) and unrelated cord blood
(UCB). We obtained data from hospital registrations to study all treatment related
activities. Unit prices were based both on real costs and tariffs (base year 2010).
Thereafter, the average costs per patient per PBSCT and per period were calculated.
The total cost included the selection and harvesting, transplantation and 1-year
follow-up. RESULTS: The average cost per patient of autoPBSCT were € 45,670. The
cost of sibling alloPBSCT were € 101,919. The average cost of transplantations from
an unrelated donor were much higher: € 171,478 for MUD and € 254,689 for UCB
alloPBSCT. Hospital days, laboratory procedures and donor search were the largest
cost components and mainly responsible for differences between the four types of
PBSCT. None of the patient characteristics were correlated with average cost. The
costs calculated in this study are above current reimbursement. The difference is
significant (p0.043) and depending on the type of PBSCT, the shortfall varied
between 2% and 100%. CONCLUSIONS: Average cost of AutoSCT and alloSCT laid
above current reimbursement levels. Appropriate financing is necessary to guar-
antee the continuation of PBSCT in Dutch patients according to current indications.
The costs calculated in this study provide reliable input for economic evaluations.
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OBJECTIVES: Obesity has reached epidemic proportions and has many cost impli-
cations, including increases in medical spending and productivity losses in the
workplace. Many studies have found a correlation between workers obesity and
absenteeism (days missed from work) and presenteeism (losses in on the job pro-
ductivity). Our study examines the impact of a worksite weight management pro-
gram on workforce productivity. METHODS: The Work Limitations Questionnaire
(WLQ) was administered to study participants (N379) at beginning and end of 2-
year trial. Employees were asked about their productivity during the previous 2
weeks of work and to rate any impairment they had in the areas of time, physical,
mental-interpersonal and output demands on a five-point scale. The resulting
WLQ productivity loss score was converted to a percent of time lost. Using a t-test,
we compared mean productivity and BMI changes over 2 years between the study
groups. RESULTS: The intervention arm had a mean BMI of 27.85 and 27.93 at
baseline and follow-up, respectively, vs. 28.22 and 28.46 in the control arm. The
average percent lost productivity for the intervention group was no different from
that in the control group (2.20% vs. 2.37%, p0.05). At the two year follow-up, the
intervention group saw an increase in lost productivity at 2.44% and the control
group saw a decrease at 2.11%. CONCLUSIONS: Our results suggest that having a
weight management program does not necessarily improve productivity of the
workforce. Future studies should further examine the relationship between obe-
sity, weight loss and productivity as well as methods to increase productivity of the
working population.
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OBJECTIVES: Waist circumference (WC) is considered an indicator of cardiovascu-
lar and metabolic risk therefore it is important to assess electronic WC recording in
general practice. This study evaluated the level of WC recording in UK primary care
and its association with body mass index (BMI). METHODS: WC recording in The
Health Improvement Network (THIN) between 2007 and 2010 was assessed. Pa-
tients with and without WC records were counted by practice, year and BMI cate-
gory (underweight 18.5kg/m2, normal 18.5-25kg/m2, overweight 25-30kg/
m2, obese30kg/m2, no BMI record). Patients were registered at the practice for the
entire year. Only WC and BMI records during the year of interest were included.
RESULTS: From 2007-2010 there were 59,193 patients (1.4%) with a WC record. WC
recording increased over time from 0.9% of patients in 2007 to 1.6% in 2010. How-
ever, there were still 69 practices (15.7%) with no WC records during 2010. Overall,
patients with a WC record had a mean age of 60.9 years (standard deviation (SD):
17.4), mean WC of 90.4cm (SD:15.0) and 53.2% were male. Patients without a WC
record had a mean age of 49.5 years (SD:21.5) and 49.5% were male. 2.1% and 78.2%
of patients with and without a WC record respectively did not have a BMI record. Of
patients with BMI and WC, 0.7% were underweight, 20.9% normal, 36.4% over-
weight and 42.0% obese, whereas patients without WC were categorised as 2.8%,
32.7%, 33.2% and 31.3% respectively. CONCLUSIONS: Despite the WC recording
percentage being low, nearly sixty thousand patients had a WC record and record-
ing increased over time. Research would therefore benefit from investigating later
years. GPs seemed more likely to record WC for patients with high BMI, therefore
research using WC should investigate any potential bias this may introduce. Future
studies could investigate associations between WC recording and other factors.
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OBJECTIVES: The Treatment Satisfaction with Medicines (SATMED-Q) question-
naire has shown appropriate psychometric properties exploring patient=s satisfac-
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